Therapeutic and diagnostic implications of Hsp90 activation.
about
Inhibition of Hsp90 acts synergistically with topoisomerase II poisons to increase the apoptotic killing of cells due to an increase in topoisomerase II mediated DNA damageChaperoning steroid hormone signaling via reversible acetylation.Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future DirectionsFeatures of protein-protein interactions that translate into potent inhibitors: topology, surface area and affinityIdentification, design and bio-evaluation of novel Hsp90 inhibitors by ligand-based virtual screeningActivation of the heat shock response attenuates the interleukin 1β-mediated inhibition of the amiloride-sensitive alveolar epithelial ion transportHeat shock protein 90: translation from cancer to Alzheimer's disease treatment?17-AAG induces cytoplasmic alpha-synuclein aggregate clearance by induction of autophagyThe RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapiesFW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation.Hsp90/Cdc37 chaperone/co-chaperone complex, a novel junction anticancer target elucidated by the mode of action of herbal drug Withaferin ASplit Renilla luciferase protein fragment-assisted complementation (SRL-PFAC) to characterize Hsp90-Cdc37 complex and identify critical residues in protein/protein interactions.Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML)Molecular imaging of the efficacy of heat shock protein 90 inhibitors in living subjects.Loss of HDAC6, a novel CHIP substrate, alleviates abnormal tau accumulationMEK inhibition potentiates the activity of Hsp90 inhibitor 17-AAG against pancreatic cancer cells.Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemiasComparative Study of 17-AAG and NVP-AUY922 in Pancreatic and Colorectal Cancer Cells: Are There Common Determinants of Sensitivity?Cdc37 interacts with the glycine-rich loop of Hsp90 client kinasesA biochemical rationale for the anticancer effects of Hsp90 inhibitors: slow, tight binding inhibition by geldanamycin and its analogues.Inhibition of FLT3 expression by green tea catechins in FLT3 mutated-AML cellsImpaired infectivity of ritonavir-resistant HIV is rescued by heat shock protein 90AB1.Direct effects of non-antifungal agents used in cancer chemotherapy and organ transplantation on the development and virulence of Candida and Aspergillus speciesRemarkable stereospecific conjugate additions to the Hsp90 inhibitor celastrolAnti-tumor activity of WK88-1, a novel geldanamycin derivative, in gefitinib-resistant non-small cell lung cancers with Met amplification.Sulforaphane inhibits pancreatic cancer through disrupting Hsp90-p50(Cdc37) complex and direct interactions with amino acids residues of Hsp90.Combination of heat shock protein 90 and focal adhesion kinase inhibitors synergistically inhibits the growth of non-small cell lung cancer cells.Molecular mechanism of cytotoxicity induced by Hsp90-targeted Antp-TPR hybrid peptide in glioblastoma cellsGlucose-regulated protein 94 triage of mutant myocilin through endoplasmic reticulum-associated degradation subverts a more efficient autophagic clearance mechanism.Purine-scaffold Hsp90 inhibitors.Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.Therapeutic aspects of chaperones/heat-shock proteins in neuro-oncology.Down-regulation of cellular FLICE-inhibitory protein (Long Form) contributes to apoptosis induced by Hsp90 inhibition in human lung cancer cellsHodgkin's lymphoma: molecular targets and novel treatment strategies.Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy.Heat shock protein 70-binding protein 1 is highly expressed in high-grade gliomas, interacts with multiple heat shock protein 70 family members, and specifically binds brain tumor cell surfacesCisplatin abrogates the geldanamycin-induced heat shock responseFuture options for imatinib mesilate-resistant tumors.Inhibition of neuroblastoma xenograft growth by Hsp90 inhibitors.The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype.
P2860
Q25257535-706A930B-4377-4C40-871B-C3A8921A3E0CQ25257831-2D710028-8DBE-4D9D-A60B-23643F02A09AQ26799387-03EC8F1A-D6BB-4485-AAB3-20B23551F0B1Q26996645-EB56D9FE-013C-46A3-BA27-4C454D6B46C0Q28485925-05B67FE8-B4DD-4A7E-9A88-9BCF22BFCA1FQ28572134-D2F83855-74B7-42B7-A6BE-1FFCC6974B97Q30855123-D24225EC-EBDC-4B91-9B2C-45CDC9DFFE5EQ33525555-2AB8951B-CE35-41F2-A46D-DCE674ACACFFQ33563635-A50620EA-B313-4A12-B9B6-EBB264C5B3B4Q33817522-81056BF4-0702-4400-A0BE-2414566AFD35Q33826976-C3892065-2CDA-45CE-B668-9FDBE72604C2Q33966866-0004E7E9-A8A7-4127-9101-2327E99B8CD4Q34082540-6576B3A9-3C61-42BE-ADEB-348EC3543BA3Q34096497-5B7A7E1C-8765-47AD-8F88-45EABCCDBB89Q34267286-8E1AE485-A571-445D-954A-574A3DCFE14AQ34354215-82DC1085-27F4-4063-A96B-55F218551E2FQ34374079-2C6AD17A-9F4A-44C2-99B6-21AAA773B756Q34478388-E9430542-6FA3-4672-8D14-F880B82D7ADCQ34564806-0AC4A8CD-7C30-46F4-818A-AB6D9DDF9C40Q34595727-9AA29AEC-6C9E-4E67-B264-88BF81ACF1E3Q34805329-A28AB9C6-8201-4B73-8F91-C8F46D3C94E8Q35107346-15D2C52A-C1D2-4F65-953D-0EAC89FC0694Q35214605-AC7F58EC-10B4-4DC0-8EBE-2F7EF3878DD6Q35615796-1E7760BF-E4B2-40B8-B510-BB3D40486FBEQ35713152-02CB54C2-86E0-4ADB-9266-531DE0390F7AQ36066968-D9AA96BB-3FA1-4CB1-9A6B-4DD09EB8F279Q36162351-310ACAC4-3030-4698-B28A-C4A738016C7BQ36402983-464E17F0-D716-43A9-AB8C-E7A47F0DA49AQ36418920-990068D8-3C01-40E9-BCCB-F46A083A9E79Q36426208-56E1501A-F4AF-43CD-B833-9CEA056C7766Q36429460-78A69703-304A-4C88-8EF9-4F33E40622D1Q36499222-4B581587-BB41-4E90-A106-9B9678929FF4Q36571903-AA991E0F-2C2A-46AB-82C2-B3F2C88EAFE7Q36572545-BFAEBCD6-D670-4DD3-9844-D3CE10C71681Q36759577-88788AB7-462D-4E45-9839-9D16EB241C4FQ36922469-96E2569D-FF0C-431B-8BD6-820BCD020B0FQ36948038-73998E00-C5D6-436C-9EEF-B7E597D3F804Q36964688-19D90770-8D16-459F-A177-181EA304039AQ37036623-37B94388-6C94-4E86-8F8F-65CA071ECCF3Q37075845-A0F1F935-B249-4659-A301-789D1D7B3E5D
P2860
Therapeutic and diagnostic implications of Hsp90 activation.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Therapeutic and diagnostic implications of Hsp90 activation.
@ast
Therapeutic and diagnostic implications of Hsp90 activation.
@en
type
label
Therapeutic and diagnostic implications of Hsp90 activation.
@ast
Therapeutic and diagnostic implications of Hsp90 activation.
@en
prefLabel
Therapeutic and diagnostic implications of Hsp90 activation.
@ast
Therapeutic and diagnostic implications of Hsp90 activation.
@en
P2093
P1476
Therapeutic and diagnostic implications of Hsp90 activation.
@en
P2093
Adeela Kamal
Francis J Burrows
Marcus F Boehm
P304
P356
10.1016/J.MOLMED.2004.04.006
P577
2004-06-01T00:00:00Z